Drug Trial Radar · NCT01841762
Clinical Study of Macitentan in Patients With Pulmonary Arterial Hypertension to Psychometrically Validate the PAH-SYMPACT Instrument
Last checked: Nov 19, 2026Latest source record: Feb 26, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
284
Actual
Start
Apr 1, 2013
Primary completion
Nov 1, 2015
Study completion Nov 1, 2015
Sponsor
- Lead sponsor
- ActelionJohnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Apr 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
SYMPHONY is prospective, multi-center, open-label, single-arm, Phase 3b psychometric validation study of the PAH-SYMPACT, a new quality of life questionnaire for patients with pulmonary arterial hypertension. Patients will be in the study for 5 1/2 months, 4 months of which they will receive macitentan, 10 mg, once daily. The primary objectives are to demonstrate the final content validity of the PAH SYMPACT instrument, to demonstrate the psychometric characteristics of reliability and construct validity of the PAH-SYMPACT instrument, and to demonstrate the ability of the PAH SYMPACT instrument to detect change. The secondary objective is to assess the safety of macitentan in patients with pulmonary arterial hypertension. The exploratory objective is to explore the effects of macitentan on PAH symptoms and their impact (as measured by the PAH-SYMPACT) in patients with pulmonary arterial hypertension.
Conditions
- Pulmonary Arterial Hypertension
Interventions
MacitentanDrug
Macitentan tablet, dose of 10 mg, once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Development and Refinement of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT)Time frame: From Screening Visit (Day -14) to End of Treatment (EOT) Visit (Visit 4, Week 16)
- Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), With Reliability Assessed Via Test-retest Reliability.Time frame: From ePRO period 1 (Days -14 to -8) to ePRO period 2 (Days -7 to -1) in screening period.
- Validation of the Patient-reported Outcome Measure of Symptoms and Their Impact in PAH (the PAH-SYMPACT), Assessing Internal Consistency Reliability.Time frame: From ePRO period 1 (Days -14 to -8) to ePRO period 2 (Days -7 to -1) in screening period.
Locations
81 sites in 1 country. Site status is shown where the registry gives one.
Cardiovascular Associates of the Southeast, LLC
Birmingham, Alabama
University of Alabama at Birmingham
Birmingham, Alabama
Pulmonary Associates, PA
Phoenix, Arizona
Mayo Clinic Arizona
Phoenix, Arizona
Cedars-Sinai Medical Center
Beverly Hills, California
UCSF Fresno
Fresno, California
UCSD Medical Center, Pulmonary Department
La Jolla, California
VAGLAHS, VA Greater LA Healthcare System
Los Angeles, California
University of California Los Angeles
Los Angeles, California
University of California San Francisco Medical Center
San Francisco, California
Stanford University
Stanford, California
Los Angeles Biomedical Research Institute
Torrance, California
University of Colorado
Aurora, Colorado
MedStar Georgetown University Hospital
Washington D.C., District of Columbia
Medstar Washington Hospital Center
Washington D.C., District of Columbia
Bay Area Cardiology Associates, P.A.
Brandon, Florida
University of Florida Academic Health Center
Gainesville, Florida
University of Florida College of Medicine, Jacksonville
Jacksonville, Florida
Mayo Clinic
Jacksonville, Florida
Cleveland Clinic Florida
Weston, Florida
Georgia Regents University
Augusta, Georgia
Georgia Clinical Research
Austell, Georgia
Northwestern University
Chicago, Illinois
University of Chicago Medical
Chicago, Illinois
Advocate Health and Hospitals Corporation
Oakbrook Terrace, Illinois
Chest Infectious Diseases and Critical Care Associates, PC
Des Moines, Iowa
University of Iowa Hospitals & Clinics
Iowa City, Iowa
Iowa City Heart Center
Iowa City, Iowa
University of Kansas Medical Center
Kansas City, Kansas
Veritas Clinical Specialties
Topeka, Kansas
Kentuckiana Pulmonary Associates
Louisville, Kentucky
University of Louisville
Louisville, Kentucky
University of Maryland Medical Center
Baltimore, Maryland
Johns Hopkins University
Baltimore, Maryland
Tufts Medical Center
Boston, Massachusetts
Boston University Medical Center
Boston, Massachusetts
University of Michigan
Ann Arbor, Michigan
Beaumont Hospital
Troy, Michigan
Mayo Clinic
Rochester, Minnesota
Midwest Pulmonary Consultants
Kansas City, Missouri
Showing 40 of 81 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.